REJECTED: FDA demands more data for Otsuka kidney drug tolvaptan
This article was originally published in Scrip
After an FDA panel of advisers earlier this month expressed concerns over liver injury with Otsuka's tolvaptan and urged against the experimental medicine's approval as a therapy to slow kidney disease in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD), the firm's late evening 29 August revelation the agency denied the company's new drug application (NDA) came as little surprise.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.